Results 61 to 70 of about 16,400 (167)
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source
Integrated Engineering of CAR‐T Cells for Solid Tumours
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang +5 more
wiley +1 more source
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino +16 more
wiley +1 more source
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy.
Anthony R. Mato +25 more
doaj +1 more source
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi +15 more
wiley +1 more source
Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li +13 more
doaj +1 more source
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto +12 more
wiley +1 more source
Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function.
Alexander P. de Porto +7 more
doaj +1 more source

